At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PPH VanEck Pharmaceutical ETF
Pre-Mkt 10-07 08:29:51 EDT
108.17
+0.56
+0.52%
盘前108.17
+0.000.00%
07:40 EDT
High108.61Low107.00Vol222.40K
Open108.12D1 Closing107.61Amplitude1.49%
Mkt Cap1.03BTradable Cap1.03BTotal Shares9.54M
T/O24.02MT/O Rate2.33%Tradable Shares9.54M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419
MT Newswires Live  ·  6 minutes ago
Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419
AlzeCure Pharma to Present at Redeye Neurology Day
Reuters  ·  16:05
AlzeCure Pharma to Present at Redeye Neurology Day
Deutsche Bank Keeps Their Sell Rating on Novo Nordisk (0QIU)
TIPRANKS  ·  15:58
Deutsche Bank Keeps Their Sell Rating on Novo Nordisk (0QIU)
Will Drug Approvals Change Merck (MRK) Narrative
Simply Wall St.  ·  06:25
Will Drug Approvals Change Merck (MRK) Narrative
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
MT Newswires Live  ·  00:41
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
TIPRANKS  ·  00:31
Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone
TIPRANKS  ·  00:30
Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone
Novartis price target lowered to $156 from $170 at Morgan Stanley
TIPRANKS  ·  10-06 23:50
Novartis price target lowered to $156 from $170 at Morgan Stanley
General Medicine Raises $120 Mln to Build the Healthcare Store
Reuters  ·  10-06 23:33
General Medicine Raises $120 Mln to Build the Healthcare Store
General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company
THOMSON REUTERS  ·  10-06 23:20
General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company
European Shares Gain as Genmab Jumps, Bond Yields Retreat
Reuters  ·  10-06 16:51
European Shares Gain as Genmab Jumps, Bond Yields Retreat
LIVE Markets-a Health Boost for the STOXX
Reuters  ·  10-06 15:54
LIVE Markets-a Health Boost for the STOXX
Genmab at 3-Year High After Blood Cancer Drug Combination Study Results
Reuters  ·  10-06 15:18
Genmab at 3-Year High After Blood Cancer Drug Combination Study Results
AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-06 04:31
AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day
AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense
Reuters  ·  10-06 04:09
AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense
Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing
THOMSON REUTERS  ·  10-06 04:08
Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing
Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing
THOMSON REUTERS  ·  10-06 04:08
Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing
Abbvie Inc. Fy2026 Shr View $14.02
THOMSON REUTERS  ·  10-06 04:08
Abbvie Inc. Fy2026 Shr View $14.02
Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing
THOMSON REUTERS  ·  10-06 04:08
Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing
Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer
MT Newswires Live  ·  10-06 03:50
Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer
No data available

Introduction

Company Name.
VanEck Pharmaceutical ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Issue price:
--